Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unequal CAB count means US delay on MRA (mutual recognition agreement):

This article was originally published in Clinica

Executive Summary

Following a long silence on the mutual recognition agreement(MRA) between the EU and the US, which most observers had expected would be officially adopted by now, it now seems that more observed audits will need to take place in the US before full implementation can take place. Indications are that the US now wants to ensure that it has as many conformity assessment bodies as the EU (currently it has three, compared to six in the EU). The speed at which the CABs can be recognised as ready for listing will depend on industry's willingness to invite potential conformity assessment bodies based in the US to take part in observed audits. In the past, companies were slow to put themselves forward and it is unclear what the situation is now.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel